Giuseppe
Emeritus
[Source: The Lancet Global Health, full page: (LINK). Abstract, edited.]
The Lancet Global Health, Early Online Publication, 24 October 2013
doi:10.1016/S2214-109X(13)70078-0
Copyright ? 2013 Pedrique et al. Open Access article distributed under the terms of CC BY-NC-SA Published by Elsevier Ltd. All rights reserved.
The drug and vaccine landscape for neglected diseases (2000?11): a systematic assessment
Dr Belen Pedrique MD a, Nathalie Strub-Wourgaft MD a, Claudette Some PharmD b, Piero Olliaro MD c d, Patrice Trouiller PharmD e, Nathan Ford PhD f, Bernard P?coul MD a, Jean-Herv? Bradol MD g
Summary
Background
In 1975?99, only 1?1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011.
Methods
We searched databases of drug regulatory authorities, WHO, and clinical trial registries for entries made between Jan 1, 2000, and Dec 31, 2011. We defined neglected diseases as malaria, tuberculosis, diarrhoeal diseases, neglected tropical diseases (NTDs; WHO definition), and other diseases of poverty according to common definitions.
Findings
Of the 850 new therapeutic products registered in 2000?11, 37 (4%) were indicated for neglected diseases, comprising 25 products with a new indication or formulation and eight vaccines or biological products. Only four new chemical entities were approved for neglected diseases (three for malaria, one for diarrhoeal disease), accounting for 1% of the 336 new chemical entities approved during the study period. Of 148 445 clinical trials registered in Dec 31, 2011, only 2016 (1%) were for neglected diseases.
Interpretation
Our findings show a persistent insufficiency in drug and vaccine development for neglected diseases. Nevertheless, these and other data show a slight improvement during the past 12 years in new therapeutics development and registration. However, for many neglected diseases, new therapeutic products urgently need to be developed and delivered to improve control and potentially achieve elimination.
Funding
None.
________
a Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland; b Centre Hospitalier Universitaire de Grenoble, Grenoble, France; c UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland; d Centre for Tropical Medicine and Vaccinology, University of Oxford, Oxford, UK; e Universit? Joseph Fourier, Grenoble, France; f M?decins Sans Fronti?res (MSF), Geneva, Switzerland; g Centre de R?flexion sur l'Action et les Savoirs Humanitaires (CRASH), M?decins Sans Fronti?res, Paris, France
Correspondence to: Dr Belen Pedrique, Drugs for Neglected Diseases initiative (DNDi), Geneva 1210, Switzerland
-
-------
The Lancet Global Health, Early Online Publication, 24 October 2013
doi:10.1016/S2214-109X(13)70078-0
Copyright ? 2013 Pedrique et al. Open Access article distributed under the terms of CC BY-NC-SA Published by Elsevier Ltd. All rights reserved.
The drug and vaccine landscape for neglected diseases (2000?11): a systematic assessment
Dr Belen Pedrique MD a, Nathalie Strub-Wourgaft MD a, Claudette Some PharmD b, Piero Olliaro MD c d, Patrice Trouiller PharmD e, Nathan Ford PhD f, Bernard P?coul MD a, Jean-Herv? Bradol MD g
Summary
Background
In 1975?99, only 1?1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011.
Methods
We searched databases of drug regulatory authorities, WHO, and clinical trial registries for entries made between Jan 1, 2000, and Dec 31, 2011. We defined neglected diseases as malaria, tuberculosis, diarrhoeal diseases, neglected tropical diseases (NTDs; WHO definition), and other diseases of poverty according to common definitions.
Findings
Of the 850 new therapeutic products registered in 2000?11, 37 (4%) were indicated for neglected diseases, comprising 25 products with a new indication or formulation and eight vaccines or biological products. Only four new chemical entities were approved for neglected diseases (three for malaria, one for diarrhoeal disease), accounting for 1% of the 336 new chemical entities approved during the study period. Of 148 445 clinical trials registered in Dec 31, 2011, only 2016 (1%) were for neglected diseases.
Interpretation
Our findings show a persistent insufficiency in drug and vaccine development for neglected diseases. Nevertheless, these and other data show a slight improvement during the past 12 years in new therapeutics development and registration. However, for many neglected diseases, new therapeutic products urgently need to be developed and delivered to improve control and potentially achieve elimination.
Funding
None.
________
a Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland; b Centre Hospitalier Universitaire de Grenoble, Grenoble, France; c UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland; d Centre for Tropical Medicine and Vaccinology, University of Oxford, Oxford, UK; e Universit? Joseph Fourier, Grenoble, France; f M?decins Sans Fronti?res (MSF), Geneva, Switzerland; g Centre de R?flexion sur l'Action et les Savoirs Humanitaires (CRASH), M?decins Sans Fronti?res, Paris, France
Correspondence to: Dr Belen Pedrique, Drugs for Neglected Diseases initiative (DNDi), Geneva 1210, Switzerland
-
-------